New Market Report Now Available: Iran Pharmaceuticals & Healthcare Report Q3 2011

Recently published research from Business Monitor International, "Iran Pharmaceuticals & Healthcare Report Q3 2011", is now available at Fast Market Research
 
 
June 8, 2011 - PRLog -- BMI View: Iran remains a challenging market for foreign drugmakers. The difficult political situation will continue to deter foreign direct investment (FDI) into the country in general, while the developed local generic manufacturing industry continues to satisfy much of domestic demand. In fact, authorities are seeking to increase local manufacturing capacities, with recent focus also covering biological medicines. High inflation and local currency devaluation will further marginalise Iran's pharmaceutical market in terms of its commercial attractiveness. In the meantime, improvements in international relations represent upside risks to our forecasts, although the opposite would clearly increase downside risks, including those pertaining to pharmaceutical trade.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/169422_iran_pharmaceuticals_he...
------------------------------------------------------------

Headline Expenditure Projections

* Pharmaceuticals: IRR24,493bn (US$2.39bn) in 2010 to IRR28,045bn (US$2.49bn) in 2011; +14.5% in local currency terms and +4.0% in US dollar terms. Forecast down slightly from Q211 due to macroeconomic factors.
 * Healthcare: IRR293,440bn (US$28.67bn) in 2010 to IRR338,698bn (US$30.06bn) in 2011; +15.4% in local currency terms and +4.8% in US dollar terms. Forecast down marginally from Q211 due to macroeconomic factors.
 *  Medical devices: IRR8,288bn (US$810mn) in 2010 to IRR11,230bn (US$997mn) in 2011; +35.5% in local currency terms and +23.1% in US dollar terms. Forecast down marginally from Q211 due to macroeconomic factors.


Business Environment Rating: In BMI's Middle East and Africa (MEA) Pharmaceutical Business Environment Ratings (BERs) for Q311, Iran ranks 14th of the 19 markets surveyed in the region. Iran's score worsened by 7% in relation to Q211, with its Risks profile more challenging than its potential Rewards. While its large population is a theoretical advantage, the country's pricing and reimbursement regimes are considered less than ideal. Therefore, we do not envisage a drastic improvement in Iran's position within the regional matrix over the coming months.

Key Trends & Developments

* Private Iranian companies expect to construct three healthcare clinics in Dushanbe in Tajikistan, the Iranian embassy announced on February 22 2011, AsiaPlus reported. The clinics will focus on eye disorders, plastic and reconstructive surgery, and kidney and urologic diseases.


BMI Economic View: The Iranian government is benefiting significantly from the elevation in oil prices caused by political unrest in oil-producing states such as Libya, though a slowdown in tax revenues will dampen some of its gains. We believe spending is likely to increase due to ambitious investment projects, but will not increase enough to match the increase in revenues. Some of this increase may trickle down to the healthcare system, representing an upside risks to our forecasts. However, we note that the slowdown in economic activity associated with international sanctions and the country's subsidy reform programme is likely to cause tax revenues to decline.

BMI Political View: Iran's plans to re-denominate its currency, removing three zeros from the rial over the next year, is not expected to have a positive impact on the economy. The underlying factors affecting the country's economy will not change as a result of the redenomination and the only impact we expect is a rise in fiscal expenditure due to the costs of printing and issuing a new currency. Therefore, this increase in expenditure associated with currency re-denomination carries downside risks for healthcare and other public sector spending.

Partial Table of Contents:

SWOT Analysis
- Table: Iran Pharmaceuticals And Healthcare Industry SWOT
- Iran Political SWOT
- Iran Economic SWOT
- Iran Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa - Pharmaceutical Business Environment Ratings Q311
- Rewards
- Risks
Iran - Market Summary
- Registration of Imports
- Generic Registration
- Intellectual Property (IP) Regime
- Intellectual Property Disputes
- Counterfeit Medicines
- Pricing and Reimbursement
- Recent Pricing and Reimbursement Developments
Industry Trends and Developments
- Epidemiology
- HIV/AIDS Situation
- Table: Iran HIV/AIDS Prevalence
- Healthcare Sector
- Healthcare Spending
- Primary Care
- Secondary Care
- Health Insurance
- International Healthcare Collaboration
- Traditional Herbal Remedies
- Research and Development
- Clinical Trials
- Biotechnology
- Medical Devices
Industry Forecast Scenario
- Overall Drug Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Iran - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Export & Import Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Domestic Pharmaceutical Sector
- Table: Iran - Leading Drug Manufacturers in the Iranian Year to March 20 2009
- Pharmaceutical Wholesale
- Table: Iran - Leading Distributors in the Iranian Year to March 20, 2008

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1694...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
End
Source:
Email:***@fastmr.com Email Verified
Phone:1.800.844.8156
Zip:01267
Tags:Medicines, Pharmaceutical, Iranian, Currency, Healthcare, Additionally, Patients, Purchasing, Subsidy
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Daily News
Weekly News



Like PRLog?
9K2K1K
Click to Share